Pieris Pharmaceuticals, Inc. stock is down -7.61% since 30 days ago. The next earnings date is Mar 27, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 40% of the previous 9 March’s closed higher than February.
Pieris Pharmaceuticals, Inc. develops anticalin proteins that are low molecular-weight therapeutic proteins derived from lipocalins. Its lead respiratory Anticalin-based drug candidate includes PRS-060/AZD1402, a drug candidate that is in Phase II clinical trial targeting IL-4Ra for the treatment of asthma and other inflammatory diseases. The company also develops a 4-1BB/ HER2 bispecific program addressing undisclosed targets for immuno-oncology diseases.
Unlock Exclusive Market Insights! Receive timely updates on market developments. Sign up & stay informed!